Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: Connecticut Children's Medical Center, Farmington, Connecticut
Conditions: Spinal Muscular Atrophy (SMA)
Craving Network Neurofeedback
Recruiting
This project tests whether individuals with overweight or obesity and high craving can learn to change their brain response to food cues using neurofeedback, to impact their craving and eating behavior.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/30/2025
Locations: Yale MRRC Anlyan Center, New Haven, Connecticut
Conditions: Overweight or Obesity
Minimally Displaced Femoral Neck Fracture Pilot Study
Recruiting
The goal of this randomized pilot study is to assess feasibility of the trial and to collect information to inform the design of a definitive trial. Adult patients ages 60 years or older with a low-energy minimally displaced femoral neck fracture (FNF) treated with surgery will be eligible to participate in the study. Patients will be randomized to one of two treatment groups, hip arthroplasty or internal fixation. Participants will be followed for 1 year.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/29/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Femoral Neck Fractures
A Study of DF6002 Alone and in Combination With Nivolumab
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Solid Tumors
Evaluation of Topical ATR12-351 in Adults with Netherton Syndrome
Recruiting
The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Netherton Syndrome
Fecal Microbiota Transplant National Registry
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: Yale New Haven Hospital, Hamden, Connecticut
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Yale University, New Haven, Connecticut
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting
The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
01/24/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: NAFLD
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
Recruiting
The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/24/2025
Locations: Clinical Site 1, New Haven, Connecticut
Conditions: Healthy Volunteers
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Recruiting
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
01/22/2025
Locations: Upsher-Smith Clinical Trial Site #1, Stamford, Connecticut
Conditions: Migraine Disorders
Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans
Recruiting
When untreated, eating disorders present with tremendous burdens to affected active duty Service members and Veterans and their families, and are very costly to the DoD and VA healthcare system. A comparative effectiveness study with state-of-the-art virtual treatment for BN and BED specifically adapted for testing with the Veteran population and other underrepresented eating disorder populations will lead to major improvements in clinical outcomes. The treatment will be integrated with VA's new... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Binge-Eating Disorder, Bulimia Nervosa, Veterans Health, Cognitive Behavioral Therapy